Dr. Benjamin A. Teply, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Nebraska College of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 191
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Nebraska College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NE license 29950 -
Student in an Organized Health Care Education/Training Program
MI license 4301096611
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Nebraska Medical Center Omaha, NE
- Bellevue Medical Center Bellevue, NE
- Faith Health Norfolk, NE
- Great Plains Health North Platte, NE
Medical groups
- Unmc Physicians (1,518 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 191
- Services billed
- 606
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 206 | 103 |
| Established patient office or other outpatient visit, 40-54 minutes | 175 | 75 |
| Established patient office or other outpatient visit, 20-29 minutes | 44 | 38 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xtandi (enzalutamide) | 100 |
| Abiraterone Acetate | 99 |
| Prednisone Other prescribers in Omaha, NE | 70 |
| Levothyroxine Sodium Other prescribers in Omaha, NE | 56 |
| Nubeqa (darolutamide) | 35 |
| Cabometyx (cabozantinib s-malate) | 34 |
| Lenvima (lenvatinib mesylate) | 31 |
| Inlyta (axitinib) | 21 |
| Eliquis (apixaban) Other prescribers in Omaha, NE | 21 |
| Prochlorperazine Maleate Other prescribers in Omaha, NE | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $33,873 in research payments for these studies, mostly to the institutions running them.
- MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer mCRPC Previously Treated With …
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.